Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype by Kristiansen, G et al.
Endogenous myoglobin in human breast cancer is a hallmark of
luminal cancer phenotype
G Kristiansen*,1, M Rose
2, C Geisler
2, FR Fritzsche
3, J Gerhardt
1,CL u ¨ke
4, A-M Ladhoff
4, R Knu ¨chel
2, M Dietel
4,
H Moch
1, Z Varga
1, J-P Theurillat
1, TA Gorr
5,6 and E Dahl
2,6
1Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland;
2Institute of Pathology, University Hospital
of the RWTH, Aachen, Germany;
3Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland;
4Institute of Pathology,
Charite ´ – Universita ¨tsmedizin Berlin, Berlin, Germany;
5Institute of Veterinary Physiology, University of Zurich, Zurich, Switzerland
BACKGROUND: We aimed to clarify the incidence and the clinicopathological value of non-muscle myoglobin (Mb) in a large cohort of
non-invasive and invasive breast cancer cases.
METHODS: Matched pairs of breast tissues from 10 patients plus 17 breast cell lines were screened by quantitative PCR for Mb mRNA.
In addition, 917 invasive and 155 non-invasive breast cancer cases were analysed by immunohistochemistry for Mb expression and
correlated to clinicopathological parameters and basal molecular characteristics including oestrogen receptor-a (ERa)/progesteron
receptor (PR)/HER2, fatty acid synthase (FASN), hypoxia-inducible factor-1a (HIF-1a), HIF-2a, glucose transporter 1 (GLUT1) and
carbonic anhydrase IX (CAIX). The spatial relationship of Mb and ERa or FASN was followed up by double immunofluorescence.
Finally, the effects of estradiol treatment and FASN inhibition on Mb expression in breast cancer cells were analysed.
RESULTS: Myoglobin mRNA was found in a subset of breast cancer cell lines; in microdissected tumours Mb transcript was markedly
upregulated. In all, 71% of tumours displayed Mb protein expression in significant correlation with a positive hormone receptor status
and better prognosis. In silico data mining confirmed higher Mb levels in luminal-type breast cancer. Myoglobin was also correlated to
FASN,
HIF-2a and CAIX, but not to HIF-1a or GLUT1, suggesting hypoxia to participate in its regulation. Double immunofluorescence
showed a cellular co-expression of ERa or FASN and Mb. In addition, Mb levels were modulated on estradiol treatment and FASN
inhibition in a cell model.
CONCLUSION: We conclude that in breast cancer, Mb is co-expressed with ERa and co-regulated by oestrogen signalling and can be
considered a hallmark of luminal breast cancer phenotype. This and its possible new role in fatty acid metabolism may have
fundamental implications for our understanding of Mb in solid tumours.
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Human myoglobin (Mb) is considered to be one of the best-
characterised proteins, with more than 11200 PubMed-listed
publications, since Kendrew and co-workers presented the first
three-dimensional model of this molecule in 1958 (Kendrew, 1958).
It is commonly described as a cytoplasmic hemoprotein that
is solely occurring at milli- to micromolar concentrations in
cardiac myocytes and type I and IIa skeletal muscle fibres of
mammals. In myocytes, Mb is widely accepted to function as
temporary ‘store’ for oxygen (O2), able to buffer short phases
of exercise-induced increases in O2 flux during which it supplies
the gas to mitochondria (Ordway and Garry, 2004). Another, more
controversially discussed role is Mbs’ facilitation of O2 diffusion
within muscle cells (Wittenberg, 1970; Ju ¨rgens et al, 1994).
Although Mb knockout mice exhibited normal exercise
capacity and no signs of compromised cardiac energetics due to
multiple systemic compensations (Garry et al, 1998; Go ¨decke et al,
1999), follow-up studies stressed the importance of functional
Mb in maintaining nitric oxide (NO) homeostasis in
muscle through either scavenging (Flo ¨gel et al, 2001) or producing
the NO molecule (Hendgen-Cotta et al, 2008). That way, Mb
might participate in tuning vasodilatory responsiveness and
protecting the respiratory chain from NO inhibition (Brunori,
2001). Further possible functions of Mb in muscle include
synthesis of peroxides (Khan et al, 1998), scavenging of reactive
O2 species (Flo ¨gel et al, 2004) and binding of fatty acids (FAs)
(Masuda et al, 2008).
In humans, Mb is synthesised at concentrations of
B200–300mM in striated muscle and, although at much lower
levels, in a variety of human tumours including medullomyo-
blastoma (Smith and Davidson, 1984), thymolipoma (Iseki et al,
1990), acute leukaemia (Ruck et al, 1995) and desmoplastic small
round cell tumours (Zhang et al, 2003). Following an accidental Received 8 March 2010; revised 12 April 2010; accepted 26 April 2010
*Correspondence: Dr G Kristiansen; E-mail: glen.kristiansen@usz.ch
This paper was presented in part at the XV International Conference on
Dioxygen Binding and Sensing Proteins Meeting in Aarhus, Denmark,
2008.
6These two authors are co-senior authors.
British Journal of Cancer (2010) 102, 1736–1745
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sobservation of positive Mb staining in several human carcinomas
in 2001, we have systematically examined Mb expression in human
breast cancer. Very recently, Flonta et al (2009) described Mb in
solid tumours including 31 breast cancer cases; however, this small
cohort size precluded further statistical analyses. Now, we are
presenting the first comprehensive analysis of Mb expression in
a large and representative cohort of human breast tissues
encompassing normal tissue (n¼56), ductal carcinoma in situ
(DCIS, n¼155), invasive breast cancer (n¼917) and breast cancer
recurrences (n¼76), enabling a portrayal of the associations
between clinicopathological parameters and the range of Mb
synthesis seen in mammary carcinomas. We also shed some light
on unusual functions of Mb in cancer by looking at the impact of
steroids on the steady state level of the protein and by examining
Mb’s involvement in FA metabolism.
MATERIALS AND METHODS
Clinical materials and patients
The matched tumour/normal samples of invasive ductal breast
carcinomas and corresponding normal breast epithelium (n¼10)
analysed in this study have recently been described (Veeck et al,
2006). For immunohistochemistry, our study included tissue
microarrays of normal tissue, intratumoural DCIS, invasive breast
cancer and breast cancer recurrences of patients diagnosed at the
Institute of Surgical Pathology (University Hospital, Zurich,
Switzerland), as described (Theurillat et al, 2007). Tumour
histology was determined according to the criteria of the
(Tavassoli and Devilee, 2003), whereas staging the disease followed
(Sobin and Wittekind, 2002). Tumours were graded according to
Bloom and Richardson, as modified by Elston and Ellis (1993).
Clinicopathological characteristics of the patients/tumours are
given in Table 1. For statistical analysis, only cases with clinical
follow-up data were considered. The median observation time for
overall survival was 59 months for patients still alive at the time of
analysis. In total, 225 patients (24%) died during follow-up. Data
on adjuvant therapy was not available. Appropriate review board
consent has been obtained to allow the use of these materials for
research purposes.
Cell lines
The human mammary epithelial cell line MCF12A, as well as the
breast cancerous cell lines BT20, BT474, Cal51, EFM19, HBL100,
Hs578T, MDA-MB231, MDA-MB361, MDA-MB453, MDA-MB415,
MDA-MB436, MDA-MB468, MCF7, SKBR3, T47-D and ZR75-1
were obtained from the ATCC (Rockville, MD, USA) and cultured
under recommended conditions.
Quantitative real-time reverse transcription PCR
For quantitative PCR experiments, we used the ABI Prism 7500
Fast SDS (Applied Biosystems, Darmstadt, Germany) with
the following primers: Mb (111bp) 50-GGCATCATGAGGCAGA
GATT-30 and 50-TCTGCAGAACCTGGATGATG-30; glyceraldehyde
Table 1 Clinicopathological parameters of invasive breast cancer cases and relation to myoglobin expression
Characteristic Number of cases (%) Mb negative Mb weak Mb moderate Mb strong P-value
917 (100%)
o60 years 416 (45.4%) 125 132 130 29 0.170
a
X60 years 501 (54.6%) 142 157 142 60
Pre-menopausal 198 (21.5%) 67 64 60 7 0.007
a
Post-menopausal 719 (78.5%) 200 225 212 82
Invasive ductal 739 (80.6%) 214 221 228 76 0.375
b
Invasive lobular 125 (13.6%) 39 49 29 8
NOS 53 (5.8%) 14 19 15 5
pT1 335 (36.5%) 91 108 106 30 0.479
a
pT2 410 (44.7%) 115 134 119 42
pT3 66 (7.2%) 27 19 17 3
pT4 106 (11.6%) 34 28 30 14
pN0 346 (42.5%) 92 107 111 36 0.355
a
pN1 369 (45.3%) 113 120 105 31
pN2 69 (8.5%) 21 20 16 12
pN3 31 (3.8%) 10 8 12 1
G1 126 (13.7%) 30 40 46 10 0.001
a
G2 460 (50.2%) 112 155 141 52
G3 331 (36.1%) 125 94 85 27
ER negative 163 (18.7%) 78 45 34 6 0.001
a
ER positive 709 (81.3%) 171 226 231 81
PR negative 314 (34.8%) 114 104 82 14 0.001
a
PR positive 588 (65.2%) 145 183 187 73
HER2—0, 1+, 2+ 776 (88.1%) 223 241 239 73 0.346
a
HER2—3+ 105 (11.9%) 33 37 25 10
Ki-67 p10% 466 (54%) 132 149 139 46 0.985
a
Ki-67 410% 393 (46%) 117 115 121 40
CK5/6 negative 793 212 260 239 82 0.001
a
CK5/6 positive 96 45 22 26 3
Abbreviations: ER¼oestrogen receptor; Mb¼myoglobin; NOS¼not otherwise specified; PR¼progesteron receptor.
aw
2-test for trends.
bPearson’s w
2-test.
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s3-phosphate dehydrogenase (289bp) 50-GAAGGTGAAGGTCGGA
GTCA-30 and 50-TGGACTCCACGACGTACTCA-30; b-actin (185bp)
50-GGACGACATGGAGAAAATC-30 and 50-ATAGCACAGCCTGGA
TAGC-30.
Western blots
MDA-MB468 cells were harvested with a lysis buffer containing
0.1% NP-40, 400mM NaCl, 1mM EDTA (pH 8.0), 10mM Tris-HCl
(pH 8.0) and protease inhibitors. Protein extracts were electro-
phoresed on a 15% SDS–PAGE gel. Monoclonal antibody mouse
anti-Mb (clone Z001, Zymed Laboratories, San Francisco, CA,
USA) was used for immunoblotting (1:1000 dilution). For equal
loading control, blots were stripped and re-probed by monoclonal
antibody mouse anti-b-actin at a 1:5000 dilution (no. A5441,
Sigma-Aldrich, Basel, Switzerland).
Immunohistochemistry and immunofluorescence
Tissue sections were processed using automated immunohisto-
chemistry platforms (BOND, Labvision (Fremont, CA, USA) and
Benchmark, Ventana (Tucson, AZ, USA)) using the following
antibodies and dilutions: Mb, clone Z001, Zymed Laboratories
(1:300); fatty acid synthase (FASN), clone 3F2-1F3, Abnova
(Taipei, Taiwan) (1:2000); HIF-1a, clone mgc3, Abcam (Cam-
bridge, UK) (1:400); HIF-2a, rabbit polyclonal, Novus Biologicals
(Littleton, CO, USA) (1:150); glucose transporter 1 (GLUT1),
rabbit polyclonal, Chemicon (Temecula, CA, USA) (1:1000);
carbonic anhydrase IX (CAIX), rabbit polyclonal, Abcam
(1:300). Immunohistochemistry was evaluated by two clinical
pathologists (GK, Florian Rudolf Fritzsche). Intensity of Mb,
GLUT1, CAIX and FASN was semiquantitatively scored as
negative, weakly, moderately or strongly positive (0–3þ).
Oestrogen receptor-a (ERa)/progesterone receptor (PR)/HIFs were
evaluated in percent of positive nuclei. Double immunofluores-
cence (Mb/ER and Mb/FASN) was performed as described
(Kristiansen et al, 2008).
Electron microscopy
Tissues from two breast tumours were fixed with 2.5% glutaral-
dehyde, postfixed with osmium tetroxide, embedded in epoxy
resin, cut with an ultramicrotome, mounted on 200 mesh copper
grids, stained with uranyl acetate and lead citrate and examined
with a Zeiss EM10 transmission electron microscope (Zeiss,
Oberkochen, Germany) at 60kV.
Expression of Mb gene after incubation of MCF-7 cells with
b-estradiol
MCF7 cells (8 10
5) were seeded into a 10cm culture dish, and
24h later, 17-b-estradiol (Sigma-Aldrich, Deisenheim, Germany)
dissolved in 5ml absolute ethanol was applied to the cells at a final
concentration of 0pM,2 0p M,4 0p M and 60pM. Cells without 17-b-
estradiol and ethanol served as internal control.
Expression of Mb gene after incubation of MDA-MB-468
cells with the FASN inhibitor C75
MDA-MB-468 cells (3 10
5) were seeded into six-well plates and
exposed to 10mgml
 1 final concentration of the FASN inhibitor
C75 (Sigma-Aldrich, St Louis, MO, USA) for 8, 24 and 48h. The
RNA and proteins were isolated according to standard procedures.
Statistical analysis
Expression data were analysed using the software package SPSS,
version 16.0 (SPSS Inc, Chicago, IL, USA). Fisher’s exact and
w
2-tests for trends were used to assess the statistical significance of
associations between Mb expression and clinicopathological
parameters (Table 1). Univariate survival analysis was performed
with univariate Cox analyses and Kaplan–Meier curves (Log-rank
test). Bivariate correlations according to Spearman were applied to
the immunointensity of normal tissue, intraductal and invasive
carcinomas.
RESULTS
Human breast cancer tissue exerts a complex pattern of
Mb expression
Mb is detectable on mRNA level in cell lines and human breast
tumours Following the initial observation of Mb immunoreactivity
in conventional immunohistochemistry analyses, Mb transcript
levels were determined in breast biopsies and breast cell lines.
Whereas low levels of Mb mRNA were detectable in 4 of 10 cases of
healthy breast tissue (Figure 1A), Mb expression was upregulated in
9 of 10 matched normal/tumour tissue samples with a median
tumour-to-normal upregulation of 352-fold. With regard to breast
cell lines, Mb mRNA was not detectable in benign MCF12A
epithelial cells, as well as in MDA-MB436, Hs578T and Cal51 tumour
cells (Figure 1B). In all, 10 breast cancer cell lines (MDA-MB231 to
MCF7, Figure 1B) expressed detectable but low amounts of Mb
mRNA, whereas 3 breast cancer cell lines contained abundant
quantities of the Mb transcript, that is, EFM19, MDA-MB415 and
MDA-MB468 cells. Regarding the protein abundance, we used a
commercial chemiluminescence-based Mb assay and determined
the amount of Mb protein present in normoxic 10
6 MDA-MB468
cells to correspond to B65ng or 4pmol (which, assuming a mean
cell diameter of 20 mm and sphere shaped cells, roughly corresponds
to a Mb concentration estimate in the low mM range).
Large-scale immunohistochemical analysis of Mb protein in
breast tissues Using a validated monoclonal Mb antibody
(Supplementary Figure S1), we next analysed Mb expression on
tissue microarrays containing normal tissue (n¼56), intra-
tumoural DCIS (n¼155), invasive breast cancer (n¼917,
clinicopathological parameters are given in Table 1) and 76
recurrences of invasive tumours. In normal breast tissue, staining
was observed in secretory luminal epithelial cells, but not in
myoepithelial cells (Figure 1C, arrowhead), with single secretory
cells (bold arrow) staining considerably stronger than adjacent
secretory cells (Figure 1C, thin arrow). Altogether, in normal
breast tissue, 7% of cases were completely negative for Mb, 49%
were weakly positive, 39% stained moderately positive and 5%
of tissues stained strongly (Supplementary Figure S2). Ductal
carcinoma in situ showed altogether a more abundant Mb staining
(Figure 1D): 12% of DCIS cases were negative, 38% weakly
positive, 39% moderately positive and 11% were strongly positive.
In invasive carcinoma, the number of Mb-negative cases was
markedly higher than in normal tissue: 29% were negative, 32%
were weakly positive, 30% were moderately positive (Figure 1E)
and 9% were strongly positive (Figure 1F). A spotted, mosaic-like
expression pattern was frequently seen in DCIS and invasive
carcinoma (Figure 1E). In tumour recurrences, 30% cases were Mb
negative, 22% weakly positive, 33% moderately positive and 15%
stained strongly (Supplementary Figure S2). Apparently, although
the mean Mb positivity is not significantly altered during
malignant progression, an increasing polarisation in Mb expres-
sion is noted in the increased number of negative and strongly
positive cases from normal tissue to tumour recurrences.
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sElectron microscopy: Mb is found without striated muscle
elements
As Mb has been described as a marker of rhabdomyoid
differentiation, we analysed two breast tumours with strong
Mb immunoreactivity by transmission electron microscopy
(Supplementary Figure S3A and B). However, no striated muscle
elements could be observed in these cases, suggesting that
increased expression of Mb occurs independently of rhabdomyoid
tumour differentiation.
Mb expression in invasive breast cancer shows a complex
correlative pattern to endogenous markers of Hypoxia
(HIF-1a, HIF-2a, GLUT1 and CAIX)
A subset of invasive breast cancer cases (n¼150) was additionally
analysed for protein level expression of the hypoxia-
inducible (transcription) factors 1a and 2a (HIF-1a, HIF-2a),
which are generally considered as the key regulators of the
hypoxic response in cells and tissues, and their down stream
targets GLUT1 and CAIX. Myoglobin expression correlated
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Figure 1 Detection of myoglobin (Mb) mRNA and protein in clinical breast cancer samples and cell lines. (A) MB mRNA expression in 10 randomly
chosen samples of human breast cancer and corresponding normal breast tissues (no. 1 to no. 10), as measured by quantitative RT-PCR. Calculation of error
bars according to Applied Biosystems user manual. Median myoglobin expression was up to 352-fold upregulated in breast tumours (grey) compared with
matching normal breast tissues (white). (B) Myoglobin mRNA expression in benign MCF12A breast cells and various breast cancer cell lines. (C) Normal
lobular parenchyma of the breast, illustrating a mild Mb immunoreactivity in luminal epithelial cells (inner layer, thin arrow), whereas myoepithelial cells (outer
cell layer, arrowhead) are negative. Note, that single luminal cells (bold arrow) are highlighted by a stronger Mb immunostaining ( 400). (D) Strong
myoglobin positivity in a ductal carcinoma in situ (DCIS), low grade, tissue showing a slight accentuation of staining in the centre in support of O2-diffusion
gradients contributing to the Mb expression profile in tissues ( 200). (E and F) Examples of invasive ductal carcinoma of the breast (all  200). (E)
Moderately differentiated with a moderate-to-strong and patchy Mb expression. In addition, note the central normal duct (arrow) with the Mb-positive
secretory cell layer and the Mb-negative myoepithelial layer. (F) Strong Mb immunoreactivity in a well-differentiated carcinoma.
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ssignificantly with HIF-2a and CAIX, but failed to correlate with
HIF-1a or GLUT1 (Table 2).
Tumour-derived Mb expression is linked to oestrogen
receptor status and better prognosis, and may represent a
marker for luminal-type breast cancer
In invasive breast carcinomas, Mb expression was associated with
better histological tumour differentiation according to BRE
grading (correlation coefficient (cc)¼ 0.116; P¼0.001). Myoglo-
bin did not correlate with pT stage, nodal status or tumour type.
Myoglobin expression was positively correlated with ERa and PR
positivity (cc¼0.206, P¼0.001 and cc¼0.180, P¼0.001) and
negatively with the myoepithelial/basal phenotype marker CK5/6
(cc¼ 0.120, P¼0.001). No significant correlation was found with
Her2, Ki-67 fraction or CD34-microvessel density.
Towards the prognostic value of Mb and clinicopathological
parameters, a univariate Cox analysis confirmed histological
tumour grade, pT stage, nodal status and hormone receptor
(ERa/PR) status as significant predictors of overall survival in our
patient cohort (Supplementary Table 1). High Mb expression was
also significantly associated with longer overall patient survival
(5-year survival rate of Mb-positive cases was 83% vs 75% in
Mb-negative cases, Figure 2A), but lost significance in a multi-
variate Cox analysis that included pT, pN, BRE-grade, ERa and Mb
(not shown). In a multivariate survival analysis restricted to ERa,
PR (as markers of luminal phenotype) and Mb, only PR remained
a significant prognosticator (HR¼0.62, P¼0.004), whereas Mb
yielded a trend towards a prognostic value (HR¼0.75, P¼0.06)
and ERa showed none at all (HR¼0.74, P¼0.11). However, in a
Kaplan–Meier analysis stratifying tumours in groups that were
either (a) negative for ERa and Mb, (b) positive for ERa or Mb or
(c) positive for both ERa and Mb, it became apparent that Mb does
add some prognostic information to the ER status (Supplementary
Figure S4), as tumours that were either positive for Mb or ER
showed an intermediate course in comparison with tumours that
were negative or positive for both markers (P¼0.001).
We additionally classified Mb levels in correlation with a
publicly available breast cancer expression data set (Farmer et al,
2005) (GEO profiles, http://www.ncbi.nlm.nih.gov/sites/entrez,
GDS1329). Here, Mb levels are significantly higher (P¼0.005,
Kruskal–Wallis test) in the group of luminal tumours compared
with basal or apocrine types. These findings along with the positive
correlation of Mb with ERa, the better tumour differentiation with
improved prognosis and the negative correlation with the basal
phenotype marker CK5/6 all point to Mb as a marker of luminal
tumour differentiation. This association of Mb with characteristics
of the luminal tumour subtype, namely, ERa positivity, led us to
investigate this point further.
Mb expression is regulated by oestrogen signalling in silico
and in vitro, and co-localises with the ER
Publicly available DNA array expression data (Geoprofiles,
GDS2324) (Coser et al, 2003) had already indicated a tight
co-regulation of Mb and ERa mRNAs in the breast cancer cell line
MCF7 by showing that oestrogen starvation was able to induce,
while oestrogen application suppressed, Mb and ERa transcripts in
either a time- or dose-dependent manner (Supplementary Figure
S5; ERa¼ESR1 in figure). We repeated this experiment and could
confirm the in silico data in vitro also, in that application of 17-b-
estradiol to ERa-positive MCF7 breast cancer cells repressed Mb
expression dose dependently (Figure 2B).
This co-silencing of ERa and Mb expression by oestrogen
application to a breast cancer cell line prompted us to analyse the
spatial association of both proteins by double immunofluores-
cence. In normal lobular breast parenchyma, B90% of the strongly
Mb-positive secretory cells, interspersed in the secretory cell
layer that we had already noted in the chromogenic immuno-
histochemistry, showed a cellular co-localisation (Figure 2E, left)
of cytoplasmic Mb (Figure 2C, left) and nuclear ERa (Figure 2D,
left) staining. In invasive breast carcinomas, this co-expression still
was apparent in well-differentiated carcinomas (Figure 2E, right),
whereas in moderately–poorly differentiated tumours, this overlap
was less prominent (not statistically evaluated).
Non-respiratory functions of non-muscle Mb?
The amount of Mb detected in human breast cancer tissue and
MDA-MB468 cells was similar in western blot analysis (data not
shown) and equalled 65ng per 10
6 tumour cells, as described
above. As this minute amount of Mb is unlikely to have a
significant role in the maintenance of cellular oxygenation, Mb
functions alternative to respiratory support have to be considered.
Recently, Mb was described as a FA-binding protein and suggested
to have a role in the transport of FAs in oxygenated cells (Gloster
and Harris, 1977; Yackzan and Wingo, 1982; Masuda et al, 2008).
This prompted us to investigate the possible co-localisation of Mb
and FASN in both healthy and cancerous breast tissue. Fatty acid
synthase catalyses the synthesis of unbranched FAs and is
upregulated in the broad majority of malignant tumours
(Menendez and Lupu, 2007). In a direct comparison of FASN
expression with Mb in a subset (n¼293) of our breast cancer
cohort, a highly significant correlation of both proteins was found
(cc¼0.297, P¼0.001). Moreover, in normal breast tissues, again, a
striking spatial concordance in the expression of Mb and FASN
was seen (Figure 3A–C, left), which was also partially retained in
cancer (Figure 3A–C, right).
To check for a possible functional association of Mb expression
and intracellular FA levels, we used the FASN inhibitor C75. This
inhibitor has been characterised as FASN specific, leading to an
almost immediate and irreversible enzyme inhibition (Kuhajda
et al, 2000). In MDA-MB468 cells, we observed a strong time-
dependent downregulation of Mb on transcript (Figure 3D, left)
and protein level (Figure 3D, right) on FASN inhibition in
comparison with control cells, suggesting that non-muscle Mb
expression is indeed regulated by intracellular FA levels. Thus, Mb
in breast carcinomas and cancer cells might be involved in
controlling FA metabolism.
DISCUSSION
This report is the first systematic examination of Mb expression in
a large cohort of breast cancer specimens that allows clinical and
molecular correlations and, furthermore, points to unexpected
functional facets of this hemoprotein. We first noticed a
supposedly aberrant Mb immunoreactivity in a small series of
breast carcinomas. To address whether Mb is being actively
produced by breast cancer cells or rather taken up from, for
example, adjacent musculature, as suggested by Eusebi et al more
than 25 years ago (Eusebi et al, 1984), we analysed its expression
both in vitro and in vivo. On transcript level, we found Mb to be
Table 2 Correlation of myoglobin expression to endogenous markers of
hypoxia (cc; P-value)
HIF-1a HIF-2a GLUT1 CAIX
Mb 0.095; 0.276 0.293; 0.001  0.039; 0.64 0.286; 0.001
HIF-1a 0.215; 0.020 0.334; 0.001 0.285; 0.001
HIF-2a  0.206; 0.024 0.223; 0.015
GLUT1 0.252; 0.003
Abbreviations: CIAX¼carbonic anhydrase IX; GLUT1¼glucose transporter 1;
HIF¼hypoxia-inducible factor.
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sstrongly upregulated in breast tumours in comparison with
adjacent normal ductal tissue. Myoglobin mRNA was also
detectable in breast cancer cell lines, in a small subset, even at
surprisingly high levels. This underscored the active expression of
endogenous Mb in ordinary invasive ductal breast cancer, which
were neither muscle-invasive nor did they, as assessed by light
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Figure 2 Myoglobin (Mb) expression is linked to better prognosis and oestrogen receptor (ER) positivity and inversely related to oestrogen
concentration. (A) Kaplan–Meier analysis of a cohort of 917 primary breast cancer cases showing that tumours with high Mb expression (Mbþ) show a
significant prognostic value for the patient of an improved cumulative overall survival compared with cases with low Mb expression (Mb ). (B) Myoglobin
expression in MCF7 breast cancer cells is repressed by increasing concentrations of 17-b-estradiol (dissolved in ethanol), as measured by quantitative reverse
transcription (RT)-PCR. (C) Normal breast tissue (left) shows a weak immunofluorescence for Mb in the secretory cell layer, of which some stronger
staining cells are intermingled. (D) The immunofluorescence for ERa (left) shows nuclear staining of single cells also. (E)The merged figure (left) illustrates,
that these cells, highlighted by ERa and Mb, are mostly corresponding (all  400). (C–E) This co-expression is also shown in a well-differentiated invasive
ductal breast carcinoma (panels on right hand side) (all  200).
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smicroscopy, exhibit any rhabdomyogenous differentiation. Trans-
mission electron microscopy also did not reveal any striated
muscle elements in two strongly Mb-positive breast cancer cases.
We therefore conclude that Mb is de novo expressed in breast
cancer cells, although rare cases of so-called metaplastic carcino-
mas of the breast might exist in which Mb positivity stems from
the rabdomyogenous differentiation of the cells (Jamieson and
Rudland, 1990; Yang et al, 2003).
On the basis of these encouraging preliminary findings, a large
recently described (Theurillat et al, 2007) cohort of primary breast
cancer, including 917 cases of invasive carcinomas and 155 cases of
DCIS, was analysed for Mb expression. Specificity of the Mb
antibody was confirmed through the peptide blockage of the
immunohistochemical signal (Supplementary Figure S1). In total,
40% of invasive carcinomas showed moderate-to-strong Mb
expression and the rate is even slightly higher in DCIS. However,
Mb was also consistently seen in mature secretory epithelia of the
healthy breast, showing a basal expression in most cells and with
a particularly pronounced expression in ERa-positive cells, as we
noted later. Contrary to earlier reports that found normal epithelia
to be invariably Mb negative (Flonta et al, 2009), luminal cells in
healthy breast clearly have the ability to express Mb at detectable
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Figure 3 Double immunofluorescence (myoglobin (Mb)/fatty acid synthase (FASN)) staining of breast tissues and regulation of Mb by inhibition of FASN.
(A) Normal breast tissue (panel on the left) shows weak immunofluorescence for Mb in the secretory cell layer, along with some stronger staining cells that
are intermingled. (B) The immunofluorescence for FASN (middle) shows strong cytoplasmic staining. (C) The overlay figure (bottom) illustrates high degree
of correspondence (yellow) between cells expressing Mb and FASN (all  400). In invasive carcinomas (panel on the right), a greater variation is seen and
co-expression of Mb and FASN is only preserved in a subset of cells as the overlay illustrates. In general, the FASN expression exceeds Mb immunoreactivity
(all  200). (D) Reverse transcription (RT)-PCR evidence for C75-mediated downregulation of Mb mRNA (left). Western blot evidence for C75-mediated
downregulation of Mb protein (right).
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slevels. The recently published study of Flonta et al (2009),
which was published during the preparation of this paper,
identified endogenous Mb in various human cancer cell lines
and human epithelial tumours including breast cancer and
elucidated several signals, including NO, oxidative stress and
mitogens (EGF and serum growth factors) and also hypoxia, that
were able to stimulate Mb expression in cultivated MCF7 breast
cancer cells. However, their study, which encompassed only 31
breast cancer cases, lacked any prognostic or detailed clinico-
pathological data.
Regarding its occurrence in breast cancer, we found that Mb is
preferentially detected in better-differentiated, hormone receptor-
positive tumours and is associated with a significantly better
prognosis. According to Perou et al (2000), all these features are
characteristics of the so-called luminal subtype of breast cancer,
which shares many molecular similarities with normal secretory
epithelia, including a strong expression of cytokeratins typical of
mature secretory epithelia (CK8/18), hormone receptor (ERa/PR)
positivity and negativity for HER2 and the basal cell cytokeratins
CK5/6. Further support for considering Mb as a diagnostic marker
of the luminal breast cancer subtype comes from the in silico
analysis of Farmer et al’s data, in which Mb transcript levels were
highest in tumours classified as the luminal subtype (Farmer et al,
2005). Our immunofluorescent double stainings further detected
co-localisation of cytoplasmic Mb and nuclear ERa in secretory
cells of normal breast tissue. The same intracellular co-localisation
was found in strongly Mb- and ERa-positive invasive ductal
carcinomas. Beyond this spatial co-existence, Mb and ERa
transcripts are also co-ordinately and dose-dependently down-
regulated when MCF7 cells are subjected to an oestrogenic
(E2¼17-b-estradiol) treatment protocol, as shown by in silico
(Supplementary Figure S5) and in vitro (Figure 3B) analyses. In
this context, it is of relevance to highlight the observation of Cheng
et al (2005), who described the inverse relationship of E2 and ERa
(which we found to be co-expressed with Mb) levels in normal
breast epithelia during the mammalian menstrual cycle. These
authors further point out that elevated expression of ERa,
occurring, for example, in postmenopausal women as a result of
the loss of E2 signalling, is indicative of non-proliferating breast
cells. The hitherto undescribed co-regulation of Mb with ERa by
oestrogen likely underlies the co-expression of ERa with Mb in
differentiated luminal cells with their reduced proliferation, which,
in turn, might explain the favourable prognosis of Mb-positive
tumours. The negative association of tumoural Mb expression and
a pre-menopausal status further fits the interpretation of Mb as an
oestrogen-silenced gene, as pre-menopausal patients (high oestro-
gen serum levels) have, in comparison with postmenopausal
patients (lower oestrogen serum levels), tumours with lower Mb
expression levels. In any instance, as the prognostic value of Mb is
limited in comparison with ER or PR, we do not suggest its use as a
primary marker to identify luminal phenotype carcinomas for
therapy planning. However, Mb might gain clinical relevance if it
could be validated as a novel therapy target of cancer, for example,
by applying carbon monoxide in sub-toxic concentrations, as has
been suggested by Dr Wittenberg at the O2BIP meeting in Aarhus
in 2008, which clearly warrants further study. This is more
important, as luminal-type breast cancer, although generally more
favourable in course, does not respond well to conventional
chemotherapy (Bhargava et al, 2010).
Myoglobin has different known or alleged functions in muscle
tissue including short-term O2 storage and buffering, facilitating
O2 diffusion, scavenging of NO and ROS and also the reverse
(peroxidase activity, NO production) and might be involved in FA
metabolism (Wittenberg, 1970; Wittenberg et al, 1975; Khan et al,
1998; Flo ¨gel et al, 2001, 2004; Ordway and Garry, 2004; Hendgen-
Cotta et al, 2008; Masuda et al, 2008). The functions of Mb in non-
muscle tissues are elusive so far. More than 50 years after
Thomlinson’s and Gray’s pioneering discovery to link radio-
sensitivity with O2 tension in tumour tissue (Gray et al, 1953;
Thomlinson and Gray, 1955), the existence of regional hypoxia in
most solid tumours (for review see Vaupel et al, 1991; Thews et al,
1998; Brown, 1999; Brown and Wilson, 2004) including breast
cancer is of high clinical relevance (Vaupel et al, 1992). Using the
exogenous hypoxia marker pimonidazole, Arcasoy et al (2002)
concluded from a series of 26 breast cancer cases that 62% of
tumours of the breast are pimonidazole-positive and thus hypoxic.
As this rate of positivity is in the range of Mb positivity that we
observed in breast cancer, we had originally hypothesised to find
an association of Mb with tissue hypoxia. In addition, the
demonstration of hypoxia-driven Mb induction in a cell line
model by Flonta et al (2009) fitted this interpretation very well.
However, our in vivo data, correlating Mb expression with
acknowledged endogenous markers of hypoxia, revealed a rather
more complex and heterogeneous picture. There was no correla-
tion with HIF-1a and its target gene GLUT1, which could either
mean that Mb is not significantly regulated by hypoxia in vivo or
that HIF-1a is insufficiently present and active because of the
amelioration of tissue hypoxia by expressed Mb. However, given
the picomole concentrations of Mb protein that we have measured
per million of the maximal Mb-producing MDA-MB468 cell line
(Figure 1B), the latter scenario is rather unlikely to explain this
lack of correlation. On the other hand, there is a significant
correlation of Mb to HIF-2a and the HIF-1/HIF-2 target gene CAIX,
which is in line of at least a partial control of Mb expression by
hypoxia. Yet, expression of Mb in breast epithelia can clearly be
regulated irrespective of O2 levels (that is, signals in normal
secretory ductal cells). The fact that Mb in breast malignancies
links with HIF-2a rather than HIF-1a results perhaps from the
mutually exclusive status between active HIF-1a and ERa/PR
signalling in breast cancer cells (Kurebayashi, 2003; Massaad-
Massade, 2004). In this sense, it is the positive correlation between
Mb and ERa/PR positivity that might preclude a significant linkage
of Mb with HIF-1a. All this evidence only underscores the complex
regulation of the Mb gene in breast carcinomas, in which hypoxia/
HIF signalling is just one of several stimuli to modulate the
abundance of this hemoprotein.
To our knowledge, so far only two studies have investigated the
functions of Mb in vivo models using artificial Mb expression
systems. Nitta et al (2003) induced Mb expression in hepatocytes by
an adenoviral gene transfer in rodents, with the effect that these
hepatocytes were significantly more hypoxia resistant. Galluzzo
et al (2009) were the first to introduce Mb into tumour cell lines and
engineered A549 human lung carcinoma cells to ectopically express
mouse Mb. Their experimental Mb-expressing tumours displayed
reduced or no hypoxia, minimal HIF-1a levels, decreased vessel
density and finally a more differentiated cancer cell phenotype. In
addition, largely suppressed local and distal metastatic spreading
was observed. The authors assume that these beneficial outcomes of
Mb overexpressing tumours result primarily from the reduction of
tumour hypoxia (Galluzzo et al, 2009). Although it is tempting to
compare their mouse model in vivo findings with our in vivo
observations from human patients, given that higher Mb levels
correlate with less aggressive tumour behaviour, both situations are
quite different. We have estimated the amount of endogenous Mb
in normoxic MDA-MB468 breast cancer cells to equate to B65ng
or 4pmol of Mb protein present in 10
6 cells. This quantity is
certainly far below the high micromolar levels reached by the
lentiviral gene transfer (Galluzzo et al, 2009). Although such
excessive amounts of ectopic Mb in tumour cells can, with reason,
be assumed to have a significant impact on tumour respiration and
tumour growth, the endogenous picomole quantities of Mb we
detected are unlikely to confer meaningful O2 storage/buffering
capacity to the cell, as already mentioned above. Thus, for these
cells, functions of Mb that are not directly linked to the binding and
transport of O2 have to be considered to understand the
physiological relevance of this protein in breast cancer.
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relevant for tumour cells is the control of FA metabolism. In a
multitude of tumours, growth is accompanied with increased FA
synthesis, and consequently enzymes catalysing these steps are
upregulated and can be used diagnostically and therapeutically
(for recent reviews see Menendez and Lupu, 2007 and Mashima
et al, 2009). We discovered that the co-localisation of Mb with
FASN might give a hint towards the FA-binding function of
tumour Mb. Fatty acid-binding properties of Mb have been
reported and predicted early (Lewis et al, 1968; Gloster and Harris,
1977), and have recently gained further attention (Sriram et al,
2008). According to Flo ¨gel et al (2005), lack of Mb in the heart of
knockout mice leads to a biochemical shift in cardiac substrate
utilisation from FA to glucose oxidation, which, not only
corresponds to an adaptive reduction in O2 consumption for the
equimolar production of ATP but also implicates the protein in
providing FA substrates for the mitochondrial b-oxidation break-
down in vivo. Our indirect demonstration that Mb is likely to be
regulated by intracellular FA levels, as shown by the inhibition of
FASN, now indicates a putative role for Mb in FA metabolism of
cancer cells and clearly warrants further study. Analysing the
metabolomic profiles of Mb-positive and Mb-negative breast
cancer cases should also yield relevant data to shed more light
on the putative role of Mb in FA metabolism.
In summary, Mb is endogenously expressed in normal breast
tissue and abundantly in a subset of breast cancer cases. The
strong association of Mb expression with presence of the ERa
explains the generally better prognosis of Mb-positive tumours,
compared with tumours lacking Mb. It appears that the regulation
of Mb in tumours is so far only incompletely understood. Our data
suggests that in breast cancer cells, Mb expression is regulated
by oestrogen signalling, possibly also by FA levels and hypoxia.
The prospective role of Mb in the lipid metabolism of ER-
positive tumours provides a reasonable rationale to investigate this
association in further studies, yet the role of other stimuli,
for example, NO or growth factors, also needs to be looked
at in greater detail. Taken together, these findings further
broaden our view on the role of non-muscle Mb that may have
fundamental implications for our conception of the biology of
solid tumours.
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